For Big Drug Companies, a Headache Looms
July 27, 2012
It would seem a business executive's dream: legally pay a competitor to keep its product off the market for years. Congress has failed to stop it, and for more than a decade generic drug makers and big-name pharmaceutical companies have been winning court rulings that allowed it. Until this month (Wyatt, The New York Times, 7/26).
Gilead Sciences Signs Deals With Three Indian Pharmaceutical Companies to Promote Low-Cost HIV Drugs in Developing Countries
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)